Trial Profile
A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2012 Planned number of patients changed from 112 to 162.
- 05 Mar 2010 New source identified and integrated (Moores UCSD Cancer Center; 6510).